copywrites
$NUVB Part 1:
KEY MANAGEMENT MESSAGES
1. Market leadership
- More new patient starts than all competitors combined
- Leader in total active patients across all lines (incl. long-term
patients on older TKIs) and in first line
- First-line share of new starts currently >60%
- Launch ~2x faster than earlier-generation ROS1 TKIs
(in January: "~6x" – different comparator)
2. Q3 market decline
- Overall ROS1 TKI market -15% in new starts, confirmed by IQVIA AND
ROS1 testing alerts from partner labs
- Management views it as a fluctuation, not a trend
3. Duration of therapy
- Real-world duration of therapy consistent with trial data (TRUST)
4. Competition
- No material impact of new entrants on active patient share
- New competitor used mainly in later lines, no off-label use in
TKI-naive patients
- IBTROZI the only brain-penetrant option without a CNS warning in its
label
1
14
